Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaTcH Trial: Trametinib and Hydroxychloroquine in Metastatic Refractory Pancreatic Cancer
NCT05518110Phase 2Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- May 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib and hydroxychloroquine in pancreatic cancer (PC), sponsored by Cancer Trials Ireland. Primary endpoint: Patients free of disease progression at 12 weeks. Started May 2023; status: terminated.
02
Drugs
trametinibhydroxychloroquine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05518110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518110.